Net survival of men with localized prostate cancer after LDR brachytherapy

Brachytherapy. 2024 May-Jun;23(3):329-334. doi: 10.1016/j.brachy.2024.02.006. Epub 2024 Mar 26.

Abstract

Objectives: To compare survival of patients who received LDR prostate brachytherapy relative to that of peers in the general population of England, UK.

Patients and methods: Net survival was estimated for 2472 cases treated between 2002 and 2016 using population-based analysis guidelines. Life tables adjusted for social deprivation in England from the Office for National Statistics were used to match patients by affluence based on their postcode.

Results: The median (range) age at time of brachytherapy was 66 (55-84) years, 84% resided in Southeast England, 51% under an index of deprivation quintile 5 (most affluent), 55% were clinical stage T1 and the remainder T2. Death from any cause occurred in 270 patients at a median (range) of 7 (1-17) years postimplant. Five and 10-year estimates (95% CI) of overall survival were 96% (95-97) and 90% (89-92), and net survival 103% (102-104) and 109% (107-110) respectively. The net survival remained above 100% in all age-at-treatment and clinical stage groups.

Conclusion: Net survival above 100% indicates patients survive longer than the matched general population. The study shows for the first time the net survival of patients treated with a radical therapy for localized prostate cancer in England. The impact of treatment choice on the long-term net survival advantage requires further investigation.

Keywords: Brachytherapy; LDR; Low dose rate; Net survival; Prostate cancer.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Brachytherapy*
  • England / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / radiotherapy
  • Radiotherapy Dosage
  • Survival Rate